AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01164475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Weight-Based Plerixafor
Study NCT03687424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow nasal oxygenation (HFNO)
Description: Experimental HFNO: O2 flow 40L/min, FiO2 40%
Study NCT03687424 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low-flow nasal oxygenation (LFNO)
Description: Active comparator (LFNO): O2 flow 5L/min, FiO2 40%
Study NCT01270659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl buccal tablet 100 mcg once
Study NCT01270659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl buccal tablet 200 mcg once
Study NCT01270659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/acetaminophen
Description: Oxycodone/acetaminophen 5/325 mg once
Study NCT01270659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone/acetaminophen
Description: Oxycodone/acetaminophen tablet 5/325 mg, 2 tablets one time
Study NCT03004040 — intervention group
Intervention type: BIOLOGICAL
Intervention: Flu Vaccine
Study NCT03785821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BMSO
Description: BMSO was extracted from Hualien No. 4 cultivate of bitter melon seed. BMSO were incorporated into capsules containing 0.5 g of oil. All persons took 3 capsules after each meal, i.e. 9 capsules (4.5 g of oil) daily, resulting in daily consumption of 2.3 g alpha-ESA in the BMSO group.
Study NCT03785821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: OO
Description: Olive oil (extra virgin grade) was purchased from La Espanola (Acesur, Spain). OO were incorporated into capsules containing 0.5 g of oil, identical appearance to BMSO. All persons took 3 capsules after each meal, i.e. 9 capsules (4.5 g of oil) daily.
Study NCT01456117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone once daily for up to 14 days.
Study NCT01456117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pioglitazone matching placebo once daily for up to 14 days.
Study NCT04428749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Yale Swallow Protocol
Description: The YSP is a three-step method consisting of an assessment of the patient's awareness, the patient's ability to follow simple instructions and finally the patient's ability to drink 90 ml water from a cup or by straw without stopping, choking or coughing.
Study NCT04428749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FEES (fiberoptic endoscopic evaluation of swallowing)
Description: The FEES will be performed bedside by an experienced occupational therapists. The patient will be sitting upright in a chair and be given 1) 2 spoons of applesauce, 2) 2 spoons of water, 3) several sips of water, 4) 90 ml of water. All items colored blue.~The FEES will use a single-use AMBU rhino-laryngo scope slim and the AMBU monitor. the examination will be terminated in case of aspiration below the vocal cords.
Study NCT02049632 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omission of axillary clearance
Study NCT02453022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin HBr 50 mg IR Tablet
Description: Danirixin HBr 50 mg IR Tablet is white, film-coated, oval-shaped tablet for oral administration.
Study NCT02453022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin FB 50 mg IR Tablet
Description: Danirixin FB 50 mg IR Tablet is white, film-coated, capsule-shaped tablet for oral administration.
Study NCT02453022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilosec (omeprazole) 40mg Delayed-Release capsule
Description: Prilosec (omeprazole) 40 mg delayed-release capsule is opaque, hard gelatin, apricot, and amethyst colored capsules, coded 743 on cap and PRILOSEC 40 on the body for oral administration.
Study NCT01416779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing Intervention
Description: Finding Balance Writing Intervention
Study NCT01455519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone ER
Description: Total target dose of 32 mg/day. All subjects will have a lead in for 2 weeks; then begin a 'forced' 2-week up-titration schedule as follows: 8mg/d (1 pill, 5 days), 16mg mg/d (2 pills, 5 days), and 24mg/d (3 pills, 5 days) then finally 32 mg/d (4 pills a day) for the 'stable dose' phase of the study, or identical placebo pills. If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 8 mg/day (or one pill a day), at the discretion of the PI. Subjects unable to tolerate 8 mg/day will be discontinued from the study. A 2-week down-titration will be used.
Study NCT01455519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Sugar pill
Study NCT01950702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laryngoscope assisted lightwand intubation
Description: After standard monitoring(EKG, pulse oximetry, NIBP), participants were induced with remifentanil and propofol continuous infusion, using targe-controlled infusion device with prexoygenation with 100% oxygen.~Manual in-line stabilization was applied with velcro during intubation to maintain neutral head position.~The Macintosh laryngoscope (female: 3rd blade, male: 4th blade) was inserted into the oral cavity to provide direct view of the epiglottis and then the tip of the lightwand was placed below the epiglottis.
Study NCT01950702 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lightwand intubation
Description: After standard monitoring(EKG, pulse oximetry, NIBP), participants were induced with remifentanil and propofol continuous infusion, using targe-controlled infusion device with prexoygenation with 100% oxygen.~Manual in-line stabilization was applied with velcro during intubation to maintain neutral head position.~After 2min from administration of rocuronium, the clinician holds the wand similar to a pencil, stands directly behind the patient's head, inserts the device into the side of the mouth and sweeps the tip to the midline. After confirmation of precise location via clear light source on anterior neck, endotracheal tube was inserted and withdrawn lightwand.
Study NCT01753063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Expectations
Description: Baseline Expectations survey (parent/guardian and adolescents 12 and older)
Study NCT01753063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Expectations
Description: 3 month follow up survey (parent/guardian and adolescents 12 and older)
Study NCT01977833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Calorie Breakfast (BTdiet)
Description: High Caloric Breakfast Test Diet (BTdiet): in which the majority of energy load will be consumed in the morning and with reduced dinner
Study NCT01977833 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Caloric Dinner (DTdiet)
Description: High Caloric Dinner (DTdiet): resembling a skipping breakfast plan, in which the majority of energy load will be consumed in the evening with minimal caloric content at breakfast
Study NCT04663516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: games provided by the console requiring the movement of upper body, lower body and trunk.
Study NCT02265835 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT00995878 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Focused ultrasound (MRgFUS)
Description: MRgFUS treatment will take place in a MRI machine and powerful ultrasound waves go through the abdominal wall to destroy the fibroid or fibroids. No incision is made during this treatment and light sedation is required. There are certain fibroids that may not be treated with this technique and there is no treatment of normal uterine tissue.ough the abdominal wall to destroy the fibroid.
Study NCT00995878 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine artery embolization (UAE)
Description: UAE treatment takes place on a regular x-ray machine. A small incision is made where the leg meets the trunk and a small tube is used to use very small pellets to block off the blood supply to the entire uterus. Sedation is used. Most fibroids are treated with this technique and normal uterine tissue is also affected.
Study NCT02207608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: Add hyaluronic acid to BCG Treatment
Study NCT02207608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG (Immucist®)
Description: Usual BCG treatment
Study NCT02207608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG (Immucist®)
Description: Usual BCG treatment
Study NCT01466868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2206
Description: Treatment will be administered orally once weekly, 2 hours before or after a meal, at day 1, 8, 15, 22 over a 28 day cycle period.~The starting dose level is 200 mg. 2 dose reduction are allowed (135 mg and 90 mg)in case of documented toxicity according to the specific algorithms.
Study NCT01741870 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional supplement
Description: Subjects will receive 50 g/day of a soy protein-based nutritional supplement containing 9.5 g protein, 250 kcal energy and all essential micronutrients
Study NCT01741870 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: routine care
Study NCT01741870 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: routine care
Study NCT00455871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: reduced fluence photodynamic therapy with Visudyne
Description: reduced fluence photodynamic therapy with visudyne
Study NCT00455871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: Lucentis intravitreal injection
Study NCT00302471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0429
Description: Part 1 - MK3328 of 1600 mg twice a day for 4 weeks given to men with hormone refractory prostate cancer and metastatic bone.~Disease.
Study NCT00302471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0429
Description: Part 2- MK3328 of 200 mg twice a day for 4 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
Study NCT00302471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0429
Description: Part 1- MK3328 of 800mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
Study NCT00302471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0429
Description: Part 2 - MK3328 of 400 mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
Study NCT02773225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: * CSA + Eltrombopag, evaluation after three month therapy start regarding dose escalation~* 6 month after therapy start --> evaluation and report of remission status of the study office --> unblinding by study office --> partial or complete remission Eltrombopag and slow tapering of CSA~* 12 month after therapy start --> evaluation and report of remission status --> complete and partial remission --> tapering/end of study treatment
Study NCT02773225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Eltrombopag)
Description: * CSA + Placebo, evaluation after three month therapy start regarding dose escalation~* 6 month after therapy start --> evaluation and report of remission status of the study office --> unblinding by study office --> no complete remission: CSA + Eltrombopag and evaluation 3 months after therapy start --> dose escalation~* 12 month after start of eltrombopag --> evaluation and report of remission status --> complete and partial remission --> tapering/end of study treatment
Study NCT01780064 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interviews with a psychologist
Description: interviews with a psychologist
Study NCT01780064 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires
Study NCT01780064 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires
Study NCT03494504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) administered once.
Study NCT03494504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.5%)
Description: Reproxalap Ophthalmic Solution (0.5%) administered once.
Study NCT03494504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution
Description: Vehicle Ophthalmic Solution administered once.
Study NCT03870243 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bubble CPAP
Description: To see the effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) in children with severe pneumonia
Study NCT03870243 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low flow oxygen
Description: To see the effectiveness of low flow oxygen in children with severe pneumonia
Study NCT00710580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-874
Description: SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
Study NCT00710580 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: SQ injection 50 mg BIW
Study NCT00710580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: SQ placebo injections for ABT-874 and etanercept
Study NCT03609606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D013, D326 and D337
Description: Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
Study NCT03609606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D013
Description: Daily oral administration of 1 tablet under fasting conditions for 7 days
Study NCT03609606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D326 and D337
Description: Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
Study NCT00569517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: 6-CBT based sesions
Study NCT00569517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational
Description: subjects receive one hour of nutrition education and 5 weekly phone calls
Study NCT00539942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arixtra (fondaparinux sodium)
Description: Treatment will consist of daily injections of pharmacy prepared syringes of Arixtra (fondaparinux sodium) 2.5mg. Treatment will continue for 21 consecutive days to end on post-operative day 22.
Study NCT00539942 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent compression devices (ICD)
Description: All patients will receive intermittent compression devices (ICD's) during the patient's entire hospitalization after the operative procedure. Patients randomized to the standard of care management will receive ICD's only. This represents the current standard of care at our institution at the time of initiation of the trial.
Study NCT03374852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: 500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port
Study NCT03374852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRNOX
Description: mFOLFIRNOX (given immediately after CPI-613 administration):
Study NCT02894736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix tDCS machine
Description: Soterix tDCS machine - miniCT supervised neuromodulation system
Study NCT04056832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Strip Pericardium
Description: The anterior pericardium is taken in accordance with the measurements made using an aortic annulus sizer or Ismail sizer. The diameter of the annulus valve is converted to circumference of the aortic valve according as a measure of the length of the pericardium. Measurement of aortic commissure height is done by measuring the distance between the lowest point of the valve attachment to the highest point on the commissure as a measure of pericardium width. The pericardium is immersed in 0.6% glutaraldehyde solution for 10 minutes, then rinsed and soaked with saline solution 3 times for 6 minutes each. After the pericardium becomes firm it is cut to be a single strip according to the length and width in the previous measurement. It is then sutured to the aortic valve annulus.
Study NCT04056832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Prosthetic Valve
Description: Median incision is performed at the surgical site. Sternal retractor is placed at the sternum after median sternotomy being performed. Aortic valve is measured using aortic annulus sizer. Pledgeted suture is performed for the mattress. Sutures are performed to attach the mechanical prosthetic to the aortic annulus.
Study NCT00674713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study NCT00674713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Study NCT00674713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physiological saline solution
Study NCT00674713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham acupuncture
Study NCT00674713 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ondansetron
Study NCT00674713 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Acupuncture at P6 point
Study NCT00674713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline solution
Study NCT00674713 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham acupuncture
Study NCT02239549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jumbo cold forceps polypectomy
Description: The specific jumbo cold forceps used are the Olympus EndoJaw Biopsy Forceps (open jaw diameter 8.5 mm) and the Boston Scientific RJ4 Biopsy Forceps (open jaw diameter 8.8 mm).
Study NCT02239549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy
Description: The specific cold snares used are the Boston Scientific Captiflex Extra Small Oval Flexible Snare (loop width 11 mm), the US Endoscopy Dsnare Dimunitive Polypectomy and Suction System (loop width 9 mm), or the Boston Scientific Sensation Short Throw Oval Flexible Snare (loop width of 13 mm, 27 mm, or 30 mm).
Study NCT03755128 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No investigational drugs will be administered as part of the study
Study NCT03702881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bonded Spurs associated with posterior build-ups
Description: Twenty-five patients will be treated with bonded spurs associated with posterior build-ups. The cervical portion of the palatal surfaces of the maxillary incisors and the incisal portion of the lingual surfaces of the mandibular incisors will be pumiced, rinsed, dried, and acid etched with 37% phosphoric acid. The etched surfaces will be subsequently rinsed and carefully dried. Then, the spurs will be bonded using Transbond primer/adhesive. The positions for the spurs will be chose to prevent possible future occlusal interferences The spurs will be sharpened with a carborundum disk before bonding. In addition, posterior build-ups (resin blocks) will be cemented on the functional cusps of all maxillary posterior teeth. The treatment time will be 12 months. After this time, the posterior build ups will be removed and the bonded spurs will be maintained for 12 months more, as active retention.
Study NCT03702881 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional bonded spurs
Description: Twenty-five patients will be treated only with bonded spurs. The bonding of the spurs will follow the same protocol described for the experimental group. The treatment time will be 12 months. After this time, the bonded spurs will be maintained for 12 months more, as active retention.
Study NCT02469545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Plantarum 299v
Description: Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and probiotic - 2x1 caps. per day of Lactobacillus Plantarum 299V (10mld colony forming units in 1 caps.) for 8 weeks.
Study NCT02469545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Crystalline cellulose powder
Description: Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and placebo of probiotic - 2x1 placebo caps. filled with micro-crystalline cellulose powder for 8 weeks.
Study NCT02469545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: 5-20mg daily
Study NCT02469545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 5-20mg daily
Study NCT02469545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sertraline
Description: 50-100mg daily
Study NCT02469545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: 50-100mg daily